• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jo-David Fine, MD

Arch Dermatol. 1988;124(4):523-526.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Within the past five years, our understanding of inherited epidermolysis bullosa (EB) has grown tremendously as a result of a combination of favorable conditions. First, recent advances in the fields of cell biology, applied immunology, and molecular biology have led to the development of in vitro models and in vivo markers for specific subtypes of EB. As a result, more refined and selective immunohistochemical reagents, notably polyclonal and monoclonal antibodies, are now available for diagnosis, both postnatal and prenatal, and for more basic studies aimed at elucidation of further mechanistic aspects of blister formation in this disease (J.D.F., R. Eady, MBBS, FRCP, M. Levy, PhD, unpublished observation, 1988).^1-12 Eventually, such work should result in definition of the actual causative gene defects in EB. Second, recent laboratory findings have led to the development of new treatments (ie, phenytoin, autologous epidermal cell culture-derived skin grafts) and the initiation of additional . . . [Full Text PDF of this Article]

Author Affiliations

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?